Class III antiarrhythmic agent

8 marketed 1 in Phase 3

This page covers all Class III antiarrhythmic agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels, Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors, Potassium channels (hERG); also sodium channels, beta-adrenergic receptors, and calcium channels.

Targets

Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels · Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors · Potassium channels (hERG); also sodium channels, beta-adrenergic receptors, and calcium channels · Potassium channels (hERG), sodium channels, L-type calcium channels, beta-adrenergic receptors · Potassium channels (hERG), sodium channels, calcium channels, beta-adrenergic receptors · Delayed rectifier potassium channels (hERG); sodium channels · Potassium channels (hERG, IKr); also sodium channels, calcium channels, and beta-adrenergic receptors

Marketed (8)

Phase 3 pipeline (1)